A study has discovered that giving early breast cancer patients’ palbociclib alongside hormone treatment stopped tumor growth entirely.
Potentially practice-changing data was presented at 2018 ASH Annual Meeting and Exposition (December 1–4, 2018; CA, USA), read our round-up to discover the key studies. Highlights include the CASSINI and MAIA trial data,
A report from the Institute of Cancer Research has found that cancer patients are waiting longer than ever for access to innovative drug treatments.
The KEYNOTE-040 trial has shown that a novel immunotherapy treatment can extend the lives of some patients with advanced head and neck cancer for up to 3 years or more.
A recent study has highlighted the differences in the time between the onset of noticeable symptoms and the commencement of treatment in colorectal patients worldwide.
Seven genes have been identified to be key in determining an individual’s risk for cancer relapse, specifically for stomach or esophageal cancer.
A drug targeting tyrosine receptor kinase, termed larotrectinib, has been approved for use in cases of NTRK gene fusion tumors.
Thousands of lung cancer patients in England are now eligible for a Keytruda® combination life-extending treatment through the Cancer Drugs Fund.
Researchers have demonstrated that the nutritional supplement mannose sugar, can both slow tumor growth and enhance the effects of chemotherapy in mice with multiple types of cancer.
A carcinoma-killing virus is being used as a delivery system for a protein that can specifically target cells surrounding and protecting tumors.